Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/7038
|
| Title: | Characterization of neuroblastic tumors using F-18-FDOPA PET |
| Authors: | Lu, MY;Liu, YL;Chang, HH;Jou, ST;Yang, YL;Lin, KH;Lin, DT;Lee, YL;Lee, H;Wu, PY;Luo, TY;Shen, LH;Huang, SF;Liao, YF;Hsu, WM;Tzen, KY;National Taiwan University Neuroblastoma Study Group |
| Contributors: | Institute of Molecular and Genomic Medicine |
| Abstract: | Neuroblastic tumors are childhood neoplasms that possess amino acid decarboxylase (AADC) activity and can theoretically be imaged by F-18-fluorodihydroxyphenylalanine (F-18-FDOPA) PET, a new diagnostic tool for neuroendocrine tumors. In this study, we explored the accuracy and clinical role of F-18-FDOPA PET in neuroblastic tumors. Methods: From 2008 to 2011, patients with tissue-proven neuroblastic tumors receiving F-18-FDOPA PET at initial diagnosis or during follow-ups were enrolled. The sensitivity and specificity of F-18-FDOPA PET were compared with those of I-123-metaiodobenzylguanidine (I-123-MIBG) scintigraphy and F-18-FDG PET, using tumor histology as the standard. The maximum standardized uptake value and tumor-to-liver uptake ratio on F-18-FDOPA PET were measured and correlated with AADC messenger RNA level in tumor tissue. Results: Fifty tumors from 34 patients, including 42 neuroblastic tumors and 8 lesions without viable tumor cells, were eligible for analysis. F-18-FDOPA PET successfully detected neuroblastic tumors of different histologic types in various anatomic sites, at a sensitivity of 97.6% (87.4%-99.9%) and a specificity of 87.5% (47.3%-99.7%). In tumors with concomitant studies, F-18-FDOPA PET demonstrated a higher sensitivity than I-123-MIBG scintigraphy (n = 18; P = 0.0455) or F-18-FDG PET (n = 46; P = 0.0455). Among the 18 tumors with concomitant I-123-MIBG scans, 4 tumors with viable cells were I-123-MIBG negative but were successfully detected by F-18-FDOPA PET. The tumor uptake of F-18-FDOPA significantly correlated with AADC expression (17 = 15 nonhepatic tumors; maximum standardized uptake value, P = 0.0002; tumor-to-liver uptake ratio, P < 0.0001). Conclusion: F-18-FDOPA PET showed high sensitivity and specificity in detecting and tracking neuroblastic tumors in this preliminary study with a small cohort of patients and might be complementary to I-123-MIBG scintigraphy and F-18-FDG PET. By correlating with AADC expression, F-18-FDOPA PET might serve as a useful imaging tool for the functional assessment of neuroblastic tumors. |
| Date: | 2013-01 |
| Relation: | Journal of Nuclear Medicine. 2013 Jan;54(1):42-49. |
| Link to: | http://dx.doi.org/10.2967/jnumed.112.102772 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0161-5505&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:000313606800028 |
| Cited Times(Scopus): | http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84872046559 |
| Appears in Collections: | [黃秀芬] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| ISI000313606800028.pdf | | 445Kb | Adobe PDF | 494 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
